DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09
NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓

2026-08-10 · BOTH · TopGLP1Providers Data Desk

What happened to compounded GLP-1s, date by date

Between late 2024 and mid-2026, compounded tirzepatide and semaglutide went from a mass market to a narrow, patient-specific lane. The hinge events: the FDA declared the tirzepatide shortage resolved in October 2024 (reaffirmed December 19, 2024) and the semaglutide shortage resolved February 21, 2025; enforcement discretion for compounders then ended on a staggered schedule through spring 2025; a federal court upheld the FDA on May 7, 2025; and on April 30, 2026 the agency proposed removing all three GLP-1s from the 503B bulk-compounding list outright. What survives is 503A compounding on individual prescriptions with documented clinical need.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

The mass market existed because of a legal exception, not despite the rules. When an FDA-approved drug is on the official shortage list, compounding pharmacies may produce what are otherwise prohibited "essential copies." Tirzepatide entered shortage in 2022 and semaglutide in 2023, and a multibillion-dollar telehealth economy grew inside that window. The window closed in stages. For tirzepatide: shortage declared resolved October 2, 2024 and confirmed that December; 503A pharmacies lost enforcement discretion February 18, 2025; 503B outsourcing facilities lost it March 19, 2025. For semaglutide: resolution declared February 21, 2025, with 503A discretion ending April 22 and 503B ending May 22, 2025. The Outsourcing Facilities Association sued over both determinations; courts denied its injunctions, and the May 7, 2025 ruling upholding the FDA — now on appeal to the Fifth Circuit — settled the enforcement posture in practice.

2026 tightened the lane further. On April 1, 2026 the FDA clarified that continued production of essential copies outside shortage conditions invites enforcement up to seizure and injunction. On April 30, 2026 it proposed striking semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, finding no clinical need for outsourcing facilities to compound them from raw ingredients; the comment period closed June 29, 2026 and a final rule is pending as of this writing. Along the way came formulation crackdowns: the agency has long warned against unstudied salt forms (tirzepatide sodium, semaglutide acetate), and a March 2026 safety finding on tirzepatide–B12 combinations undercut the most popular "personalization" recipe — by late 2025, more than four in five compounded GLP-1 prescriptions added B vitamins or amino acids at least partly to argue the product was not a copy.

So what is actually legal in August 2026? Brand tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy, and the oral Wegovy pill launched January 2026) are fully approved and increasingly price-competitive through LillyDirect↗ ($299–$449 vials) and NovoCare↗ ($349 standard). Compounded versions remain lawful only as patient-specific 503A prescriptions where the prescriber documents a need an approved product cannot meet — a genuinely narrower standard than "it's cheaper," and one enforced unevenly across states. "Research use only" peptides sold online sit outside the law entirely for human use, whatever the label says. Every compounded program in our index should be read against this backdrop, and the ones worth considering are the ones that behave like they know it: named 503A/503B pharmacy networks, real prescriber screening, and prices published plainly enough to be held to. That is, not coincidentally, exactly what our methodology scores.

This is a regulatory summary current to 2026-08-09, not legal advice; the proposed rule's final form could move the lines again.

The cheapest compounded tirzepatide online rigThe cheapest compounded semaglutide online, inCompounded tirzepatide vs ZepboundWhat a year of tirzepatide actually costs, proDose-flat vs dose-tiered pricing